Dr. Elizabeth Hudson is the Founder and CEO of Ambitious Bio, a life sciences AI infrastructure company building foundational biological data infrastructure for the AI era, headquartered in Cambridge, Massachusetts.

Dr. Hudson earned her undergraduate degree from Yale University and completed a Ph.D. in neuroscience, before transitioning into industrial robotics at Symbotic and later serving as CTO at a Boston-based biotech venture capital firm.

A distinguished neuroscientist and proven AI, robotics, and technology executive, Dr. Hudson was also honored as a Forbes 30 Under 30 in Law and Policy in 2017, and serves as an Intelligence Officer in the United States Navy Reserve.

Prior to Ambitious Bio, Dr. Hudson held roles spanning industrial robotics at Symbotic, CTO at a biotech VC firm, and Vice Chair of the Advisory Board at the Harvard and Smithsonian Center for Astrophysics.

Ambitious Bio emerged from stealth in June 2026, defining a new category in life sciences, and in proteomics alone already maps more of the human proteome, tissue by tissue, than the public reference behind today's leading research tools.